Mycophenolat 1 A Pharma (Mycophenolate Mofetil)

Mycophenolate Mofetil, the active ingredient in Mycophenolat 1 A Pharma, is an immunosuppressant presented as a [strength]/[form] for oral use. It is employed to prevent organ transplant rejection and to treat autoimmune conditions such as lupus nephritis in adult patients.

GNH USA supplies Mycophenolat 1 A Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Mycophenolate Mofetil is used to modulate immune activity in transplant and autoimmune disease pathways. - Organ transplant rejection: helps prevent graft rejection by suppressing lymphocyte proliferation. - Lupus nephritis: reduces renal inflammation and proteinuria in patients with systemic lupus erythematosus. - Other autoimmune diseases (off‑label): may be employed to manage conditions such as vasculitis or dermatomyositis where immune suppression is required.

Mycophenolate Mofetil may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: frequent loose stools. - Headache: transient cranial pain. - Infections: increased susceptibility to bacterial or viral infections.

Serious or Rare Side Effects: - Severe infections: opportunistic infections such as CMV or PCP. - Bone marrow suppression: leukopenia, anemia, or thrombocytopenia. - Hepatic toxicity: elevated liver enzymes or hepatitis. - Progressive multifocal leukoencephalopathy (PML): rare demyelinating disease.

When prescribing Mycophenolate Mofetil, several precautions should be observed to ensure patient safety. - Monitor blood counts: perform regular complete blood count to detect leukopenia or anemia. - Assess liver function: check hepatic enzymes periodically. - Avoid use in pregnancy: drug is contraindicated (Category X) and requires effective contraception. - Counsel on contraception: both male and female patients should use reliable birth control methods. - Adjust for renal impairment: dose may need reduction in patients with reduced kidney function. - Store at below 25°C: keep in the original packaging, protect from moisture and light.

Mycophenolate Mofetil interacts with several medicines that can alter its efficacy or safety profile.

Major Interactions (Avoid): - Live vaccines: may cause uncontrolled infection due to immunosuppression. - Strong CYP3A4 inhibitors (e.g., azole antifungals, clarithromycin): increase mycophenolate exposure and toxicity. - Antacids containing aluminum or magnesium: reduce oral absorption of mycophenolate.

Moderate Interactions (Monitor Closely): - Calcineurin inhibitors (e.g., cyclosporine, tacrolimus): additive immunosuppression may increase infection risk. - Inactivated vaccines: efficacy may be reduced; timing should be coordinated.